If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.
|Tumour Group / Site||Trial Title||Opening Date|
|Breast||Assessment of breast cancer and response to systemic therapy before surgery using diffuse optical imaging technology. (DOB-Scan)||August 2018|
|Gastrointestinal||A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859).||Mar. 26, 2019|
|Melanoma||A Phase 3, randomized, open-label study of NKTR-214 combined with Nivolumab versus Nivolumab in participants with previously untreated unresectable or metastastic melanoma (SMTCA045).||Nov.18, 2020|